Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MIGLITOL vs ALDOCLOR-250
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Reversible competitive inhibitor of alpha-glucosidase in the intestinal brush border; delays glucose absorption and lowers postprandial hyperglycemia.
Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.
Type 2 diabetes mellitus as monotherapy or in combination with sulfonylureas, metformin, or insulin when diet and exercise do not provide adequate glycemic control
Hypertension (first-line or adjunctive therapy),Off-label: Management of hypertensive crisis (as part of combination therapy)
25 mg orally three times daily with the first bite of each main meal; may increase to 50 mg three times daily after 4-8 weeks, maximum 100 mg three times daily.
250 mg orally twice daily
Plasma elimination half-life ≈ 2 hours; clinical effect (alpha-glucosidase inhibition) persists longer due to enzyme binding; half-life increases in renal impairment (creatinine clearance < 25 m L/min).
1.5-3 hours; prolonged in renal impairment (up to 20 hours with Cr Cl <10 m L/min).
Not metabolized; excreted unchanged in feces (via enzymatic breakdown in gut lumen) and urine (minor).
Methyldopa: Primarily hepatic metabolism via catecholamine pathways; conjugated to sulfate and other metabolites. Chlorothiazide: Not extensively metabolized; excreted unchanged in urine.
Primarily excreted unchanged in urine (≈ 65%) via glomerular filtration; remainder recovered as metabolites in urine (25%) and feces (5%); total recovery in urine and feces ≈ 95% within 24 hours.
Renal (70-80% unchanged), biliary/fecal (15-25% as metabolites); total clearance ~250 m L/min.
Negligible (< 4%), primarily bound to albumin.
25-40% bound primarily to albumin and alpha-1-acid glycoprotein.
Approximately 0.18 L/kg; distributes mainly in extracellular fluid with limited tissue penetration.
0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding.
Low and variable oral bioavailability: approximately 50% (range 35–65%) due to incomplete absorption and intestinal metabolism; dose proportional for doses up to 100 mg.
70-90% (oral); 100% (IV).
GFR <25 m L/min/1.73m2: contraindicated. No adjustment needed for GFR ≥25 m L/min/1.73m2.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours
No dose adjustment required for hepatic impairment; not studied in Child-Pugh C. Use with caution in severe hepatic disease.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use
Safety and efficacy not established in pediatric patients.
Not recommended for use in pediatric patients due to lack of safety and efficacy data
No specific dose adjustment, but monitor renal function; elderly may have age-related decline in renal function. Use lowest effective dose.
Start at lower end of dosing range; monitor renal function closely; adjust dose based on Cr Cl
None.
None explicitly listed. However, methyldopa carries a warning for hepatotoxicity and hemolytic anemia; chlorothiazide carries a warning for electrolyte disturbances and hypersensitivity reactions.
Hypoglycemia risk when used with insulin or sulfonylureas,Hepatotoxicity (rare, monitor liver enzymes),Gastrointestinal side effects (flatulence, diarrhea, abdominal pain) due to undigested carbohydrates in colon
Hepatotoxicity (methyldopa), hemolytic anemia, positive direct Coombs test, sedation, depression, bradycardia, orthostatic hypotension, electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, photosensitivity, lupus-like syndrome, and hypersensitivity reactions.
Diabetic ketoacidosis,Inflammatory bowel disease,Colonic ulceration,Intestinal obstruction or predisposition to obstruction,Chronic intestinal diseases associated with malabsorption,Hypersensitivity to miglitol
Active hepatic disease, history of previous methyldopa-induced liver dysfunction, hemolytic anemia associated with methyldopa, anuria, hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs, severe renal impairment (Cr Cl <30 m L/min), and concomitant therapy with MAO inhibitors.
Carbohydrates in the meal may cause increased flatulence and diarrhea. Sucrose and table sugar are not effective for treating hypoglycemia; use pure glucose. Avoid excessive simple carbohydrates if tolerated.
Avoid high-potassium foods (bananas, oranges, spinach) unless specifically advised; chlorothiazide may cause potassium loss, but methyldopa can cause potassium retention. Avoid excessive alcohol intake as it may potentiate hypotension. Take with food to reduce gastrointestinal upset. May decrease glucose tolerance; monitor in diabetic patients.
No adequate well-controlled studies in pregnant women. Animal studies show no evidence of fetal harm at doses up to 150 mg/kg in rats and 75 mg/kg in rabbits. Risk cannot be ruled out; use only if clearly needed.
FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxicity (oligohydramnios, renal failure), premature closure of ductus arteriosus, pulmonary hypertension, and intracranial hemorrhage. Avoid in third trimester.
No data on presence in human milk. M/P ratio unknown. Consider benefit of breastfeeding versus potential risk to infant.
Chlorothiazide is excreted in breast milk; M/P ratio unknown. Can suppress lactation. Use only if maternal benefit outweighs potential infant risks (e.g., electrolyte disturbances, thrombocytopenia).
No pharmacokinetic studies in pregnancy; dosing adjustments not established. Monitor glycemic control closely and adjust as needed per clinical response.
Increased volume of distribution and GFR in pregnancy may necessitate higher doses for equivalent effect. Start at lowest effective dose; titrate based on BP response. Monitor for hypokalemia and metabolic alkalosis.
Miglitol is an alpha-glucosidase inhibitor that delays carbohydrate absorption. It is not effective for type 1 diabetes. Monitor liver enzymes; cases of hepatitis have been reported. Do not use in patients with inflammatory bowel disease, colonic ulceration, or partial intestinal obstruction. Hypoglycemia must be treated with oral glucose (dextrose), not sucrose because sucrase is inhibited. Take with the first bite of each main meal.
Aldoclor-250 is a combination of methyldopa (250mg) and chlorothiazide. Methyldopa can cause a positive direct Coombs test (10-20% of patients) which may interfere with blood cross-matching; obtain a hematocrit and Coombs test before therapy and at 6 and 12 months. Chlorothiazide may cause hypokalemia; monitor potassium and consider potassium supplementation. Onset of methyldopa is 3-6 hours; delay full effect for 48-72 hours. Avoid use in patients with active liver disease or history of previous methyldopa-induced liver dysfunction.
Take miglitol three times daily at the start of each main meal (with the first bite).,If you miss a dose, skip it if the meal is already finished; do not double the dose.,Common side effects include flatulence, diarrhea, and abdominal pain; these may decrease over time.,If hypoglycemia occurs, use glucose tablets or gel; table sugar (sucrose) will not work.,Inform your doctor if you have a history of kidney disease, inflammatory bowel disease, or intestinal obstruction.
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying to prevent lightheadedness.,Report any unexplained fever, jaundice, or dark urine immediately.,Use sun protection; this drug may increase sensitivity to sunlight.,Do not use potassium supplements or salt substitutes without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it's near the next dose; do not double.
"Miglitol, an alpha-glucosidase inhibitor, delays carbohydrate digestion and absorption, reducing postprandial hyperglycemia. Stanozolol, an anabolic steroid, can increase insulin sensitivity and enhance glucose utilization, potentially leading to additive hypoglycemic effects. Concurrent use may result in unexpectedly low blood glucose levels, especially in diabetic patients on insulin or sulfonylureas."
"Miglitol, an alpha-glucosidase inhibitor, delays carbohydrate absorption and reduces postprandial hyperglycemia. Levomilnacipran, a serotonin-norepinephrine reuptake inhibitor (SNRI), may enhance insulin sensitivity or alter glucose metabolism, potentially increasing the hypoglycemic effect when combined with miglitol. This interaction could result in additive blood glucose lowering and an elevated risk of hypoglycemic episodes, particularly in diabetic patients."
"Saquinavir, a protease inhibitor used in HIV therapy, may decrease the therapeutic efficacy of miglitol, an alpha-glucosidase inhibitor for type 2 diabetes, by potentially increasing gastrointestinal motility or altering gut enzyme activity. This interaction can lead to reduced miglitol absorption and diminished postprandial glycemic control, increasing the risk of hyperglycemia in diabetic patients. Clinical outcomes include elevated blood glucose levels and potential loss of diabetes management."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MIGLITOL vs ALDOCLOR-250, answered by our medical review team.
MIGLITOL is a Alpha-Glucosidase Inhibitor that works by Reversible competitive inhibitor of alpha-glucosidase in the intestinal brush border; delays glucose absorption and lowers postprandial hyperglycemia.. ALDOCLOR-250 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MIGLITOL and ALDOCLOR-250 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MIGLITOL is: 25 mg orally three times daily with the first bite of each main meal; may increase to 50 mg three times daily after 4-8 weeks, maximum 100 mg three times daily.. The standard adult dose of ALDOCLOR-250 is: 250 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MIGLITOL and ALDOCLOR-250 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MIGLITOL is classified as Category A/B. No adequate well-controlled studies in pregnant women. Animal studies show no evidence of fetal harm at doses up to 150 mg/kg in rats and 75 mg/kg in rabbits. Risk cannot be ruled . ALDOCLOR-250 is classified as Category C. FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.